Table 3.

The relationship between SLC30A family genes and OS in different stages of GC patients (Kaplan–Meier Plotter).

	Stage	Cases	HR (95% CI)	P-value
SLC30A1	I	62	0.43 (0.14–1.31)	0.1270
	II	140	0.74 (0.37–1.5)	0.4060
	III	197	0.64 (0.43–0.96)	0.0280*
	IV	140	0.53 (0.34–0.82)	0.0037*
SLC30A2	I	62	3,777,800 (0-lnf)	0.0150*
	II	140	1.55 (0.82–2.9)	0.1710
	III	197	1.69 (1.15–2.49)	0.0067*
	IV	140	2 (1.34–3)	0.0006*
SLC30A3	I	62	2.34 (0.67–8.22)	0.1720
	II	140	1.66 (0.88–3.13)	0.1140
	III	197	1.64 (1.23–2.19)	0.0007*
	IV	140	0.75 (0.51–1.12)	0.1570
SLC30A4	I	62	3.06 (0.93–10.1)	0.0551
	II	140	1.56 (0.81–3.01)	0.1840
	III	197	1.68 (1.14–2.49)	0.0082*
	IV	140	1.6 (1.07–2.38)	0.0210*
SLC30A5	I	62	0.21 (0.07–0.64)	0.0026*
	II	140	1.65 (0.82–3.33)	0.1590
	III	197	0.58 (0.4–0.85)	0.0046*
	IV	140	0.56 (0.37–0.84)	0.0041*
SLC30A6	I	62	0.14 (0.03–0.64)	0.0033*
	II	140	0.55 (0.29–1.05)	0.0650
	III	197	0.57 (0.38–0.84)	0.0042*
	IV	140	0.48 (0.31–0.74)	0.0007*
SLC30A7	I	62	0.19 (0.05–0.7)	0.0053*
	II	140	0.67 (0.34–1.35)	0.2630
	III	197	0.57 (0.39–0.83)	0.0031*
	IV	140	0.63 (0.41–0.98)	0.0390*
SLC30A8	I	62	4.6 (1.53–13.82)	0.0028*
	II	140	1.8 (0.88–3.69)	0.1031
	III	197	1.55 (1.07–2.25)	0.0202*
	IV	140	1.68 (1.1–2.57)	0.0160*
SLC30A9	I	62	0.22 (0.08–0.6)	0.0013*
	II	140	0.58 (0.32–1.08)	0.0850
	III	197	0.53 (0.39–0.72)	4.9e−05*
	IV	140	0.6 (0.41–0.89)	0.0100*
SLC30A10	I	62	2.88 (1.07–7.75)	0.0280*
	II	140	1.7 (0.94–3.07)	0.0780
	III	197	1.54 (1.08–2.18)	0.0150*
	IV	140	0.72 (0.45–1.14)	0.1550

a: The P-value was set at 0.05 and the * indicate that the results are statistically significant.